Small-molecule inhibitors of ALK5 display efficacy in rodent models of PAH (128, 129) but have not been evaluated in PAH patients due in part to safety concerns and the potential for off-target effects (155). This evidence concerns the gene TGFBR1 and pulmonary arterial hypertension.